Latest TRIB reports update at 2024-05-14: 202320222021
Trinity Biotech plc logo
Trinity Biotech plc TRIB
$ 1.65 -2.94%

Trinity Biotech plc Balance Sheet 2011-2024 | TRIB

Annual Balance Sheet Trinity Biotech plc

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- 55.4 M 84.5 M 51.6 M 37.2 M 19.4 M -7.29 M -7.22 M -9.03 M -11.5 M -3.1 M

Long Term Debt

- - - 82.7 M 99.8 M 81.9 M 94.8 M 96.5 M - - - - -

Long Term Debt Current

- - - - - - - - - - - - -

Total Non Current Liabilities

- - - 106 M 107 M 90 M 106 M 116 M 130 M 23.8 M 22.5 M 15 M 6.9 M

Total Current Liabilities

- - - - - - - - - - - - -

Total Liabilities

83.4 M 94.3 M 119 M 133 M 126 M 108 M 127 M 141 M - - - 28 M 20.2 M

Deferred Revenue

- - - 4.44 M - - - - - - - - -

Retained Earnings

- - - 10.6 M 16.2 M 55.3 M 47.8 M 91.3 M - - - 171 M 154 M

Total Assets

59.4 M 92.1 M 119 M 130 M 131 M 152 M 193 M 250 M - - - 197 M 172 M

Cash and Cash Equivalents

3.69 M 6.58 M 25.9 M 27.3 M 15.2 M 30.3 M 57.6 M 77.1 M 102 M - - - -

Book Value

-23.9 M -2.18 M -319 K -2.22 M 4.71 M 44.1 M 65.2 M 109 M - - - 169 M 151 M

Total Shareholders Equity

- - - -2.22 M 4.71 M 44.1 M 65.2 M 109 M 214 M - - - -

All numbers in USD currency

Quarterly Balance Sheet Trinity Biotech plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 18.7 M - - - 106 M - - - 107 M - - - 90 M - 107 M 107 M 107 M - - - 116 M - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - 119 M - - - 133 M - - - 126 M - - - 108 M - 128 M 129 M 128 M - - - 141 M - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - 12.6 M - - - 10.6 M - - - 16.1 M - - - 55.3 M - 47.4 M 46.8 M 75.8 M - - - 110 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 119 M - - - 130 M - - - 131 M - - - 152 M - 194 M 195 M 193 M - - - 250 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 25.9 M - - - 27.3 M - - - 15.2 M - - - 30.3 M - 49.4 M 53.9 M 57.6 M - 64 M 69.9 M 77.1 M - - - 102 M - - - 9.1 M - - - - - - - - - - - - - - -

Book Value

- - - - -319 K - - - -2.22 M - - - 4.71 M - - - 44.1 M - 66.7 M 65.8 M 65.2 M - - - 109 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - -319 K - - - -2.22 M - - - 4.71 M - - - 44.1 M - 66.7 M 65.8 M 65.2 M - - - 109 M - - - 214 M - - - 197 M - - - - - - - - - - - - - - -

All numbers in USD currency